To confirm the synergistic anti-tumor activity of adding the anti-CTLA-4 antibody to the combination of anti-PD-1 antibody and B. longum 420, we next performed further animal studies using the Renca-bearing BALB/c mouse RCC syngeneic tumor model. This evidence concerns the gene CTLA4 and renal cell carcinoma.